Acetylsalicylic acid ( ASA ) did not reduce stroke or ' all cardiovascular events ' compared to placebo in primary prevention patients with elevated blood pressure and no prior cardiovascular disease .
Antiplatelet therapy with ASA for primary prevention in patients with elevated blood pressure provides a benefit , reduction in myocardial infa rct ion , which is negated by a harm of similar magnitude , increase in major haemorrhage .
The benefit of antiplatelet therapy for secondary prevention in patients with elevated blood pressure is many times greater than the harm .
Benefit has not been demonstrated for warfarin therapy alone or in combination with aspirin in patients with elevated blood pressure .
BACKGROUND Elevated systemic blood pressure results in high intravascular pressure but the main complications , coronary heart disease ( CHD ) , ischaemic strokes and peripheral vascular disease ( PVD ) , are related to thrombosis rather than haemorrhage .
Some complications related to elevated blood pressure , heart failure or atrial fibrillation , are themselves associated with stroke and thromboembolism .
Therefore it is important to investigate if antithrombotic therapy may be useful in preventing thrombosis-related complications in patients with elevated blood pressure .
OBJECTIVES To conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with high blood pressure , including those with elevations in both systolic and diastolic blood pressure , isolated elevations of either systolic or diastolic blood pressure , to address the following hypotheses : ( i ) antiplatelet agents reduce total deaths and /or major thrombotic events when compared to placebo or other active treatment ; and ( ii ) oral anticoagulants reduce total deaths and /or major thromboembolic events when compared to placebo or other active treatment .
Ticlopidine , clopidogrel and newer antiplatelet agents such as prasugrel and ticagrelor have not been sufficiently evaluated in patients with high blood pressure .
Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.
Sixteen hypertensive male out- patients ( 33 - 54 y ) , whose blood pressure ( BP ) had been normalized ( diastolic BP < 90 mmHg ) by treatment with a daily dose of 50 mg atenolol ( CAS 29122 - 68 - 7 ) , participated in this double-blind , placebo-controlled , parallel group study , which investigated the possible influence of the non-steroidal anti-inflammatory drug tenoxicam ( CAS 59804 - 37 - 4 ) on the control of BP by atenolol . After a run-in of 10 days , to assess the stability of BP control by atenolol , and to determine baseline parameters , 8 patients in group A received 20 mg tenoxicam ( 2 x 20 mg on days 1 and 2 ) , and 8 patients in group B received placebo , daily over 15 days ( days 0 - 14 ) , concomitantly with their atenolol regimen .  BP was measured under st and ardized conditions on several days . Heart rate ( EHR ) after 5 min of exercise by bicycle ergometry ( constant 75W ) , and parameters of renal function were assessed before ( baseline ) and during concomitant dosing of atenolol and tenoxicam . On day 14 the mean changes ( delta A , delta B ) from baseline of pre-dose BP ( mmHg ) and EHR ( beats/min ) in groups A and B , and the one-sided 95 % confidence regions ( R ) for delta A , respectively , were ( delta A , delta B , R ) : 4.4 , 1.6 , < 9.5 for sitting systolic BP , 2.8 , -0.3 , < 4.5 for sitting diastolic BP , -0.3 , -0.6 , < 5.5 for st and ing systolic BP , -0.6 , -1.9 , < 3.0 for st and ing diastolic BP , 0.4 , -7.5 , < 0.4 for EHR at pre-dose , 3.1 , 0.6 , < 7.8 for EHR at 3.5 h post-dose . ( ABSTRACT TRUNCATED AT 250 WORDS
Acetylsalicylic acid ( ASA ) did not reduce stroke or ' all cardiovascular events ' compared to placebo in primary prevention patients with elevated blood pressure and no prior cardiovascular disease .
Antiplatelet therapy with ASA for primary prevention in patients with elevated blood pressure provides a benefit , reduction in myocardial infa rct ion , which is negated by a harm of similar magnitude , increase in major haemorrhage .
The benefit of antiplatelet therapy for secondary prevention in patients with elevated blood pressure is many times greater than the harm .
Benefit has not been demonstrated for warfarin therapy alone or in combination with aspirin in patients with elevated blood pressure .
BACKGROUND Elevated systemic blood pressure results in high intravascular pressure but the main complications , coronary heart disease ( CHD ) , ischaemic strokes and peripheral vascular disease ( PVD ) , are related to thrombosis rather than haemorrhage .
Some complications related to elevated blood pressure , heart failure or atrial fibrillation , are themselves associated with stroke and thromboembolism .
Therefore it is important to investigate if antithrombotic therapy may be useful in preventing thrombosis-related complications in patients with elevated blood pressure .
OBJECTIVES To conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with high blood pressure , including those with elevations in both systolic and diastolic blood pressure , isolated elevations of either systolic or diastolic blood pressure , to address the following hypotheses : ( i ) antiplatelet agents reduce total deaths and /or major thrombotic events when compared to placebo or other active treatment ; and ( ii ) oral anticoagulants reduce total deaths and /or major thromboembolic events when compared to placebo or other active treatment .
Ticlopidine , clopidogrel and newer antiplatelet agents such as prasugrel and ticagrelor have not been sufficiently evaluated in patients with high blood pressure .